FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) reported data demonstrating the in vitro activity of Veklury (remdesivir) against ten SARS-CoV-2 variants, including Omicron. The study showed
(Reuters) - Gilead Sciences Inc s drug, remdesivir, showed antiviral activity against Omicron, Delta and other variants of the coronavirus in laboratory studies, the company said on Friday.
11.02.2022 - Gilead Sciences, Inc. (Nasdaq: GILD) today released data demonstrating the in vitro activity of Veklury (remdesivir) against ten SARS-CoV-2 variants, including Omicron. Results of Gilead studies are consistent with other in vitro studies . Seite 1